Lucentis Archives -

Market Access/ News/ News/ News/ Sales and Marketing

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

Phil Taylor biosimilar, Byooviz, Cimerli, Coherus, Lucentis, Novartis, Roche, Samsung Bioepis 0 Comment

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

https://pharmaphorum.com/news/pressure-rises-on-lucentis-as-coherus-biosimilar-gets-fda-nod/

Market Access/ News/ News

FDA clears Roche’s Susvimo implant for eye disease wet AMD

Phil Taylor age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis, ophthalmology, Regeneron, Roche, Susvimo, wet AMD 0 Comment

Roche’s Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration

FDA clears Roche’s Susvimo implant for eye disease wet AMD

https://pharmaphorum.com/news/fda-clears-roches-susvimo-implant-for-eye-disease-wet-amd/

Market Access/ News/ News

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

Phil Taylor age-related macular degeneration, Biogen, Byooviz, Lucentis, ophthalmology, regulatory approval, Roche, Samsung Bioepis 0 Comment

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

https://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/

News/ News/ Sales and Marketing

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

Phil Taylor biosimilar, Byooviz, Lucentis, Novartis, ophthalmology, Roche, Samsung Bioepis, wet AMD 0 Comment

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

https://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/

News/ News/ Sales and Marketing

Novartis says trials back Beovu safety in diabetic eye disease

Phil Taylor Bayer, Beovu, diabetic macular oedema, Eylea, Lucentis, Novartis, ophthalmology, Regeneron 0 Comment

There is plenty of evidence that Novartis’ ophthalmology drug Beovu can match its rivals when it comes to

Novartis says trials back Beovu safety in diabetic eye disease

https://pharmaphorum.com/news/novartis-says-trials-back-beovu-safety-in-diabetic-eye-disease/

Market Access/ News/ News

Roche eyes October decision by FDA for wet AMD implant

Phil Taylor age-related macular degeneration, Beovu, Eylea, fda, Lucentis, Novartis, ophthalmology, Regeneron, Roche, wet AMD 0 Comment

The FDA has started a review of a new implant version of Roche’s ranibizumab therapy for wet age-related

Roche eyes October decision by FDA for wet AMD implant

https://pharmaphorum.com/news/roche-eyes-october-decision-by-fda-for-wet-amd-implant/

MyTherapy Novartis - See What's Next (002)

Digital/ News/ News

Novartis taps smartpatient for app to support wet AMD patients

Phil Taylor app, Beovu, digital, digital health, Lucentis, Novartis, ophthalmology, smartpatient, wet AMD 0 Comment

German digital health company smartpatient is adding a new section of its MyTherapy app providing information on wet

Novartis taps smartpatient for app to support wet AMD patients

https://pharmaphorum.com/news/novartis-taps-smartpatient-for-app-to-support-wet-amd-patients/

Market Access/ News/ News

Novartis’ blockbuster hope Beovu clears EMA advisory panel

Phil Taylor age-related macular degeneration, Bayer, Beovu, Eylea, Lucentis, Novartis 0 Comment

Novartis could launch its new age-related macular degeneration drug in Europe early next year after getting a green

Novartis’ blockbuster hope Beovu clears EMA advisory panel

https://pharmaphorum.com/news/novartis-blockbuster-hope-beovu-clears-ema-advisory-panel/

Market Access/ News/ News/ News/ Sales and Marketing

MHRA says Avastin can be used for AMD despite Bayer, Novartis objections

Phil Taylor Avastin, Bayer, Eylea, Lucentis, MHRA, Novartis, Roche, wet AMD 0 Comment

The UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration,

MHRA says Avastin can be used for AMD despite Bayer, Novartis objections

https://pharmaphorum.com/news/mhra-says-avastin-can-be-used-for-amd-despite-bayer-novartis-objections/

Trending

Lucentis

Login